Synagis (or palivizumab) is a manufactured antibody used to treat a common virus called respiratory syncytial virus, or RSV. Even though 98% of children have the virus, it is particularly dangerous and life-threatening for premature infants or infants with lung or heart disease. The Synagis vaccine is a very effective vaccine given by injection approximately every 30 days (for up to five months) for treating the virus.

Synagis is not used in generally healthy babies who can handle an RSV infection without the vaccine. It is most effective in treating high-risk RSV-infected babies and young children who are exposed to infected people and have not built up an immunity.

Monoclonal antibodies, such as palivizumab (Synagis), can be used to reduce the severity of an RSV infection.


Talk to Dr. Logan or your primary care physician about an RSV evaluation to see if Synagis is an appropriate treatment. Symptoms include a runny nose, fever and mild cough.

To learn more about Synagis and RSV, we recommend you visit the American Academy of Pediatrics Website. A link is on our Resources page.